Twice weekly pneumocystis jiroveci pneumonia prophylaxis with trimethoprim-sulfamethoxazole in pediatric patients with acute lymphoblastic leukemia

Journal of Pediatric Hematology/Oncology

Volumn 33, Issue 1, 2011, Pages

  Agrawal, Anurag K ^a   Chang, Patrick P ^b   Feusner, James ^a  

^a CHILDREN S HOSPITAL OAKLAND   (United States)

^b Children's Center for Blood and Cancer of Northern Virginia   (United States)

Author keywords

acute lymphoblastic leukemia; Pneumocystis jiroveci pneumonia; trimethoprimsulfamethoxazole (TMP SMX)

Indexed keywords

COTRIMOXAZOLE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CLINICAL PRACTICE; DRUG DOSE REGIMEN; HUMAN; INFECTION PREVENTION; MAJOR CLINICAL STUDY; PEDIATRICS; PNEUMOCYSTIS JIROVECI; PNEUMOCYSTIS PNEUMONIA; PRACTICE GUIDELINE; PRIORITY JOURNAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; PNEUMOCYSTIS JIROVECII; PNEUMONIA, PNEUMOCYSTIS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RETROSPECTIVE STUDIES; SULFAMETHOXAZOLE; TRIMETHOPRIM;

EID: 78650785516     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e3181fd6fca     Document Type: Article

References (24)

1. Hughes WT, Kuhn S, Chaudhary S, et al. Successful chemoprophylaxis for Pneumocystis carinii pneumonitis. N Engl J Med. 1977;297:1419-1426.
2. Hughes WT. Trimethoprim-sulfamethoxazole therapy for Pneumocystis carinii pneumonitis in children. Rev Infect Dis. 1982;4:602-607.
3. Arend SM, Kroon FP, van't Wont JW. Pneumocystis carinii pneumonia in patients without AIDS, 1980 through 1993. Arch Intern Med. 1995;155:2436-2441.
4. Sepkowitz KA, Brown AE, Telzak EE, et al. Pneumocystis carinii pneumonia among patients without AIDS at a cancer hospital. JAMA. 1992;267:832-837.
5. Ioannidis JPA, Cappelleri JC, Skolnik PR, et al. A metaanalysis of the relative efficacy and toxicity of Pneumocystis carinii prophylactic regimens. Arch Intern Med. 1996;156: 177-188.
6. Thomas CF, Limper AH. Pneumocystis pneumonia. N Engl J Med. 2004;350:2487-2498.
7. American Academy of Pediatrics. Pneumocystis jiroveci infections. In: Pickering LK, Baker CT, Long SS, et al. eds. Red Book: 2009 Report of the Committee on Infectious Diseases. 28th ed. Elk Grove Village, IL: AAP; 2009:540.
8. Centers for Disease Control and Prevention. 2002 USPHS/ IDSA guidelines for preventing opportunistic infections among HIV-infected persons-2002. Recommendations of the US Public Health Service and the Infectious Diseases Society of America. MMWR Recomm Rep. 2002;51:1-46.
9. Hughes WT, Rivera GK, Schell MJ, et al. Successful intermittent chemoprophylaxis for Pneumocystis carinii pneumonitis. N Engl J Med. 1987;316:1627-1632.
10. Lindemulder S, Albano E. Successful intermittent prophylaxis with trimethoprim/sulfamethoxazole 2 days per week for Pneumocystis carinii (jiroveci) pneumonia in pediatric oncology patients. J Pediatr. 2007;120:e47-51.
11. Ohata Y, Ohta H, Hashii Y, et al. Intermittent oral trimethoprim/ sulfamethoxazole on two non-consecutive days per week is effective as Pneumocystis jiroveci pneumonia prophylaxis in pediatric patients receiving chemotherapy or hematopoietic stem cell transplant. Pediatr Blood Cancer. 2009;52:142-144.
12. Souza JP, Boeckh M, Gooley TA, et al. High rates of Pneumocystis carinii pneumonia in allogeneic blood and marrow transplant recipients receiving dapsone prophylaxis. Clin Infect Dis. 1999;29:1467-1471.
13. Torre-Cisneros J, De la Mata M, Pozo JC, et al. Randomized trial of weekly sulfadoxine/pyrimethamine vs. daily low-dose trimethoprim- sulfamethoxazole for the prophylaxis of Pneumocystis carinii pneumonia after liver transplantation. Clin Infect Dis. 1999;29:771-774.
14. Jurado R, Garcia-Herola A, Garcia-Lazaro M, et al. Pyrimethamine/ sulfadoxine for prevention of Pneumocystis carinii pneumonia in patients infected with the human immunodeficiency virus. Clin Infect Dis. 1994;19:218-219.
15. Walzer PD, Foy J, Steele M, et al. Activities of antifolate, antiviral, and other drugs in an immunosuppressed rat model of Pneumocystis carinii pneumonia. Antimicrob Agents Chemother. 1992;36:1935-1942.
16. Huang L, Crothers K, Atzori C, et al. Dihydropteroate synthase gene mutations in pneumocystis and sulfa resistance. Emerg Infect Dis. 2004;10:1721-1728.
17. Ma L, Borio L, Masur H, et al. Pneumocystis carinii dihydropteroate synthase but not dihydrofolate reductase gene mutations correlate with prior trimethoprim-sulfamethoxazole or dapsone use. J Infect Dis. 1999;180:1969-1978.
18. Wilber RB, Feldman S, Malone WJ, et al. Chemoprophylaxis for Pneumocystis carinii pneumonitis. Am J Dis Child. 1980; 134:643-648.
19. Keogh A, MacDonald D, Richens A, et al. Mini-dose trimethoprim with sulfamethoxazole prevents pneumocystis and toxoplasmosis infections after heart transplantation. Transplant Proc. 1992;24:2263.
20. Vetter H, Reichenspurner H, Ü berfuhr P, et al. Inzidenz, prophylaxe und therapie der zytomegalie- ung Pneumocystis carinii-infektion nach herztransplantation. Med Klin. 1992;87: 56-59.
21. Fisher RG, Nageswaran S, Valentine ME, et al. Successful prophylaxis against Pneumocystis carinii pneumonia in HIVinfected children using smaller than recommended dosages of trimethoprim-sulfamethoxazole. AIDS Patient Care STDS. 2001;15:263-269.
22. Hughes WT, Killmar J. Monodrug efficacies of sulfonamides in prophylaxis for Pneumocystis carinii pneumonia. Antimicrob Agent Chemother. 1996;40:962-965.
23. Razavi B, Lund B, Allen BL, et al. Failure of trimethoprim/ sulfamethoxazole prophylaxis for Pneumocystis carinii pneumonia with concurrent leucovorin use. Infection. 2002;30:41-42.
24. Centers for Disease Control and Prevention. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Recommendations of the Center for Disease Control, the Infectious Disease Society of America, and the American Society for Blood and Marrow Transplantation. MMWR Recomm Rep. 2000;49:1-128.